In the last decade, cystic fibrosis transmembrane conductance regulator (CFTR) modulator (CFTRm) therapies targeting the basic molecular defect in CF have been developed and have demonstrated significant improved health outcomes, including better respiratory function, nutritional status, and enhanced quality of life (5). This evidence concerns the gene CFTR and cystic fibrosis.